Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cabaletta Bio Inc (NQ: CABA ) 6.060 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Cabaletta Bio Inc < Previous 1 2 3 Next > Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum July 02, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 June 14, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference May 29, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 12/8 December 08, 2023 Via Investor Brand Network Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 11/9 November 09, 2023 Via Investor Brand Network Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update May 15, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 13, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 21, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis March 20, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/24 October 24, 2023 Via Investor Brand Network Cabaletta Bio to Participate in Upcoming Investor Conferences in March February 27, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis February 01, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 31, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 10/23 October 23, 2023 Via Investor Brand Network Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 9/12 September 12, 2023 Via Investor Brand Network Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 8/23 August 23, 2023 Via Investor Brand Network Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis January 08, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 8/18 August 18, 2023 Via Investor Brand Network Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Cabaletta Bio Via GlobeNewswire Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform November 06, 2023 From Cellares Via Business Wire Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis November 06, 2023 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November October 30, 2023 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 October 02, 2023 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio to Participate in Upcoming Investor Conferences in September September 19, 2023 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September August 30, 2023 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 August 22, 2023 From Cabaletta Bio Via GlobeNewswire Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update August 10, 2023 From Cabaletta Bio Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.